Patent · US Active

Compositions and methods for inhibiting PDGFRβ and VEGF-A

US9441034B2 · kind B2 · utility

19Cited by
8References
61Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 27, 2009
Grant dateSep 13, 2016
Priority date
Expiry dateSep 16, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed are antagonists of PDGF receptor β (PDGFRβ) and VEGF-A, including neutralizing anti-PDGFRβ and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFRβ and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFRβ and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFRβ and/or VEGF-A antagonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.